Getz gets Port-Access in Japan:
This article was originally published in Clinica
Getz is to have exclusive distribution rights to Heartport's Port-Access minimally-invasive cardiac surgery systems in Japan. California-based Getz will obtain regulatory approvals and reimbursement for the systems as well as training Japanese surgical teams. Heartport's product allows surgeons to perform heart operations through a small incision between the ribs. Some 900,000 people in Japan have ischemic heart disease and more than 30,000 people undergo open heart surgery annually. Getz claims to be the largest healthcare export marketing and services company in the US with offices in 23 countries.
You may also be interested in...
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.
Medtechs took a long look at themselves as they rose to the challenges of COVID-19. How they responded, repurposed and regrouped to tackle the coronavirus was both sobering and uplifting. The lessons of 2020 must be integrated into the digitally-enabled health care systems of 2021 and beyond.
Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19
2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.